Excess Protein Synthesis in FXS Patient Lymphoblastoid Cells Can Be Rescued with a p110β-Selective Inhibitor
Open Access
- 7 December 2011
- journal article
- Published by Springer Nature in Molecular Medicine
- Vol. 18 (3) , 336-345
Abstract
The fragile X mental retardation protein (FMRP) plays a key role for neurotransmitter-mediated signaling upstream of neuronal protein synthesis. Functional loss of FMRP causes the inherited intellectual disability fragile X syndrome (FXS), and leads to increased and stimulus-insensitive neuronal protein synthesis in FXS animal models. Previous studies suggested that excess protein synthesis mediated by dysregulated signal transduction contributes to the majority of neurological defects in FXS, and might be a promising target for therapeutic strategies in patients. However, possible impairments in receptor-dependent protein synthesis have not been evaluated in patient cells so far. Using quantitative fluorescent metabolic labeling, we demonstrate that protein synthesis is exaggerated and cannot be further increased by cytokine stimulation in human fragile X lymphoblastoid cells. Our previous work suggested that loss of FMRP-mediated regulation of protein expression and enzymatic function of the PI3K catalytic subunit p110β contributes to dysregulated protein synthesis in a mouse model of FXS. Here, we demonstrate that these molecular mechanisms are recapitulated in FXS patient cells. Furthermore, we show that treatment with a p110β-selective antagonist rescues excess protein synthesis in synaptoneurosomes from an FXS mouse model and in patient cells. Our work suggests that dys-regulated protein synthesis and PI3K activity in patient cells might be suitable biomarkers to quantify the efficacy of drugs to ameliorate molecular mechanisms underlying FXS, and could be used for drug screens to refine treatment strategies for individual patients. Moreover, we provide rationale to pursue p110β-targeting treatments as potential therapy in FXS, and possibly other autism spectrum disorders.Keywords
This publication has 37 references indexed in Scilit:
- Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and BeyondNeuropsychopharmacology, 2011
- Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056Science Translational Medicine, 2011
- Activity of any class IA PI3K isoform can sustain cell proliferation and survivalProceedings of the National Academy of Sciences, 2010
- Status of PI3K inhibition and biomarker development in cancer therapeuticsAnnals of Oncology, 2009
- Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorderHuman Molecular Genetics, 2009
- Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and FunctionNeuron, 2008
- Excess protein synthesis in Drosophila Fragile X mutants impairs long-term memoryNature Neuroscience, 2008
- Correction of Fragile X Syndrome in MiceNeuron, 2007
- Selective identification of newly synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging (BONCAT)Proceedings of the National Academy of Sciences, 2006
- Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndromeNature Genetics, 1995